The study will evaluate the clinical activity of sitravatinib in combination with
nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in
the neoadjuvant setting prior to nephrectomy.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03680521.
Sitravatinib is a receptor tyrosine kinase inhibitor (TKI) that targets multiple closely
related receptor tyrosine kinase pathways including VEGFR, PDGFR, c-KIT, MET, and the TAM
family of receptors (TYRO3, AXL, and MER). Nivolumab is a monoclonal antibody directed
against PD-1 and blocks the interaction between PD-1 and its ligands, thereby releasing
PD-1-mediated inhibition of T-cell proliferation (including cytotoxic CD8+ T-cells) and
cytokine production. Together, sitravatinib and nivolumab may cooperate to elicit greater
anti-tumor activity than either agent alone, as sitravatinib is predicted to enhance
several steps in the cancer immunity cycle that may augment the efficacy of nivolumab.
Lead OrganizationMirati Therapeutics
